SCHEMBL5123655

SCHEMBL5123655

CC(C)(C)OC(=O)N1C[C@@H](OC(=O)c2ccccc2)C[C@H]1c1cc(-c2ccccn2)no1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.38
USP30 Q70CQ3 5/20 0.38
HCRTR2 O43614 1/20 0.38
UCHL1 P09936 1/20 0.37
SCD5 Q86SK9 2/20 0.36
HDAC8 Q9BY41 1/20 0.36
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
CHRNA7 P36544 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
ABHD6 Q9BV23 1/20 0.35
GPR119 Q8TDV5 2/20 0.35
ROCK2 O75116 1/20 0.34
SCD O00767 1/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5115026 0.90 UCHL1 (0.43) HDAC6USP30HCRTR2UCHL1SCD5
SCHEMBL5130041 0.90 UCHL1 (0.43) HDAC6USP30HCRTR2UCHL1SCD5
SCHEMBL5115001 0.88 USP30 (0.38) HDAC6USP30HCRTR2UCHL1SCD5
SCHEMBL5173319 0.88 USP30 (0.38) HDAC6USP30HCRTR2UCHL1SCD5
SCHEMBL5122491 0.86 CYP1A2 (0.41) HDAC6USP30HCRTR2SCD5HDAC8
SCHEMBL5119061 0.86 CYP1A2 (0.41) HDAC6USP30HCRTR2SCD5HDAC8
SCHEMBL5130360 0.86 CYP1A2 (0.41) HDAC6USP30HCRTR2SCD5HDAC8
SCHEMBL4908872 0.81 USP30 (0.44) USP30HCRTR2SCD5GPR119NR1H2
SCHEMBL4918972 0.81 USP30 (0.44) USP30HCRTR2SCD5GPR119NR1H2
SCHEMBL3859454 0.80 SCD5 (0.48) USP30HCRTR2SCD5GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161330-A1 Pyrimidines as Igf-I Inhibitors ASTRAZENECA AB (SE) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161330-A1 Pyrimidines as Igf-I Inhibitors IGF1R, IGFBP1, IGFBP2 HDAC6 4191/4885USP30 4042/4885HCRTR2 3051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.